NCT04579380 2025-12-19Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsSeagen Inc.Phase 2 Active not recruiting217 enrolled 19 charts
NCT02393248 2023-01-06Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)Incyte CorporationPhase 1/2 Terminated201 enrolled 71 charts
NCT05091528 2022-08-18A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive CancersSilverback TherapeuticsPhase 1/2 Terminated2 enrolled 9 charts